Apixaban Compared With Warfarin for Stroke Prevention in Atrial Fibrillation Implications of Time in Therapeutic Range

被引：11
作者：
Gallego, Pilar [1 ,2 ]
Antonio Vilchez, Juan [1 ,3 ,4 ]
Lane, Deirdre A. [1 ]
机构：
[1] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham B18 7QH, W Midlands, England
[2] Morales Meseguer Univ Hosp, Dept Hematol & Clin Oncol, Murcia, Spain
[3] Hosp Univ Virgen de la Arrixaca, Dept Cardiol, Murcia, Spain
[4] Hosp Univ Virgen de la Arrixaca, Dept Clin Anal, Murcia, Spain
来源：
CIRCULATION | 2013年 / 127卷 / 22期
关键词：
Editorials; anticoagulants; apixaban; atrial fibrillation; time in therapeutic range; warfarin; NORMALIZED RATIO CONTROL; ANTICOAGULATION CONTROL; ORAL ANTICOAGULANT; EFFICACY; OUTCOMES; QUALITY; SAFETY;
D O I：
10.1161/CIRCULATIONAHA.113.003132
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2163 / 2165
页数：3
相关论文
共 50 条
  • [31] Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study
    Kuwahara, Taishi
    Abe, Mitsunori
    Yamaki, Masaru
    Fujieda, Hiroyuki
    Abe, Yumiko
    Hashimoto, Katsushi
    Ishiba, Misako
    Sakai, Hirotsuka
    Hishikari, Keiichi
    Takigawa, Masateru
    Okubo, Kenji
    Takagi, Katsumasa
    Tanaka, Yasuaki
    Nakajima, Jun
    Takahashi, Atsushi
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2016, 27 (05) : 549 - 554
  • [32] Apixaban: An Update of the Evidence for Its Place in the Prevention of Stroke in Patients with Atrial Fibrillation
    Seeger, Julia
    Woehrle, Jochen
    CORE EVIDENCE, 2020, 15 : 1 - 6
  • [33] Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation
    Deitelzweig, Steve
    Evans, Michael
    Hillson, Eric
    Trocio, Jeffrey
    Bruno, Amanda
    Tan, Wilson
    Lingohr-Smith, Melissa
    Singh, Prianka
    Lin, Jay
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (01) : 87 - 94
  • [34] Direct Oral Anticoagulants Versus Warfarin for Atrial Fibrillation in Relation to Time in Therapeutic Range: An Analysis of US Food and Drug Administration Regulatory Data
    Boesen, Kim
    Saiz, Luis Carlos
    Gotzsche, Peter C.
    Erviti, Juan
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2025, 18 (03):
  • [35] Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and End-Stage Renal Disease: Lessons Learned
    Benz, Alexander P. P.
    Eikelboom, John W. W.
    CIRCULATION, 2022, 146 (23) : 1746 - 1748
  • [36] Quality of Stroke Prevention Care in Atrial Fibrillation Many Moving Targets
    Turakhia, Mintu P.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2011, 4 (01): : 5 - 8
  • [37] Time in therapeutic range Warfarin anticoagulation for atrial fibrillation in a community-based practice
    Gateman, Derek
    Trojnar, Melissa Elizabeth
    Agarwal, Gina
    CANADIAN FAMILY PHYSICIAN, 2017, 63 (10) : E425 - E431
  • [38] Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation
    Kamel, Hooman
    Easton, J. Donald
    Johnston, S. Claiborne
    Kim, Anthony S.
    NEUROLOGY, 2012, 79 (14) : 1428 - 1434
  • [39] Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Focus on Apixaban
    Tatjana S. Potpara
    Marija M. Polovina
    Marina M. Licina
    Radan M. Stojanovic
    Milica S. Prostran
    Gregory Y. H. Lip
    Advances in Therapy, 2012, 29 : 491 - 507
  • [40] Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Focus on Apixaban
    Potpara, Tatjana S.
    Polovina, Marija M.
    Licina, Marina M.
    Stojanovic, Radan M.
    Prostran, Milica S.
    Lip, Gregory Y. H.
    ADVANCES IN THERAPY, 2012, 29 (06) : 491 - 507
12345